98%
921
2 minutes
20
Inflammation observed in SARS-CoV-2-infected patients suggests that inflammasomes, proinflammatory intracellular complexes, regulate various steps of infection. Lung epithelial cells express inflammasome-forming sensors and constitute the primary entry door of SARS-CoV-2. Here, we describe that the NLRP1 inflammasome detects SARS-CoV-2 infection in human lung epithelial cells. Specifically, human NLRP1 is cleaved at the Q333 site by multiple coronavirus 3CL proteases, which triggers inflammasome assembly and cell death and limits the production of infectious viral particles. Analysis of NLRP1-associated pathways unveils that 3CL proteases also inactivate the pyroptosis executioner Gasdermin D (GSDMD). Subsequently, caspase-3 and GSDME promote alternative cell pyroptosis. Finally, analysis of pyroptosis markers in plasma from COVID-19 patients with characterized severe pneumonia due to autoantibodies against, or inborn errors of, type I interferons (IFNs) highlights GSDME/caspase-3 as potential markers of disease severity. Overall, our findings identify NLRP1 as a sensor of SARS-CoV-2 infection in lung epithelia.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108100 | PMC |
http://dx.doi.org/10.1016/j.molcel.2022.04.033 | DOI Listing |
Antiviral Res
September 2025
Pharmaceutical Research Division, Shionogi & Co., Ltd., 1-1, Futaba-cho 3-chome, Toyonaka, Osaka 561-0825, Japan. Electronic address:
Ensitrelvir, an oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) 3CL protease inhibitor, is reportedly effective in suppressing smell disorder onset, a post-coronavirus disease 2019 (COVID-19) condition symptom. However, the pathogenesis of post-COVID-19 condition symptoms and the mechanism underlying the onset-suppressive effect of ensitrelvir are not fully understood. Here, we explored a post-COVID-19 condition model in hamsters 1 month post-SARS-CoV-2 infection and showed that ensitrelvir treatment caused early recovery of body weight, viral RNA suppression, and sense of smell improvement.
View Article and Find Full Text PDFPhys Chem Chem Phys
September 2025
Department of Chemistry & Biochemistry, Thapar Institute of Engineering & Technology, Patiala-147004, Punjab, India.
The main protease (M, also known as 3CL), a pivotal enzyme of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has been considered a prime target for drug development due to its crucial role in viral replication and transcription. Importantly, a high degree of conservation in more than 13 million SARS-CoV-2 sequences affords M as a promising target for antiviral therapy to impede the genetic evolution of SARS-CoV-2. In this work, ∼16 million compounds from various small molecule databases were screened using ligand-based virtual screening (LBVS) with boceprevir as the reference compound to identify new small molecule inhibitors of M.
View Article and Find Full Text PDFJ Inorg Biochem
December 2025
Institute of Medicinal and Pharmaceutical Chemistry, Technische Universität Braunschweig, Beethovenstr. 55, 38106 Braunschweig, Germany. Electronic address:
Selected gold(III)-dithiocarbamato complexes were identified as potent inhibitors of two critical enzymes involved in the SARS-CoV-2 replication cycle, the papain-line protease (PL) and the 3-chymotrypsin-like protease (3CL), showing exceptional inhibition of PL with IC values in the range of 0.1-0.2 μM and rather moderate activity against 3CL (IC values 8-9 μM).
View Article and Find Full Text PDFProtein Sci
September 2025
Department of Chemistry, McGill University, Montreal, Quebec, Canada.
The emergence of SARS-CoV-2 and other lethal coronaviruses has prompted extensive research into targeted antiviral treatments, particularly focusing on the viral 3C-like protease (3CL) due to its essential role for viral replication. However, the rise of drug resistance mutations poses threats to public health and underscores the need to predict resistance mutations and understand the mechanism of how these mutations confer resistance. The binding of inhibitor to 3CL drives it from the monomeric to the active dimeric form, which can counterintuitively lead to enzyme activation rather than inhibition.
View Article and Find Full Text PDFVirol J
August 2025
Department of Infectious Diseases, Federal University of São Paulo (UNIFESP), Sao Paulo, Brazil.
Background: Remdesivir has been established as a safe treatment for patients with COVID-19. However, given the SARS-CoV-2 random mutations, 3CL protease inhibitors have been studied in recent randomized controlled trials. Therefore, this meta-analysis aims to compare 3CL protease inhibitors versus placebo in patients with mild to moderate COVID-19.
View Article and Find Full Text PDF